RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Kawasaki Disease: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Aspirin dose and coronary artery lesions in Kawasaki disease: a two-center retrospective comparative effectiveness study.
Zhao B N et al., European journal of pediatrics (17 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42891855/
- 2.
Association between post-intravenous immunoglobulin hypothermia and lower receipt of second-line therapy in Kawasaki disease: a single-center retrospective cohort study.
Arimatsu Masayuki et al., Clinical rheumatology (17 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42891890/
- 3.
Temporal drift, calibration monitoring, and adaptive updating of an IVIG resistance prediction model in Kawasaki disease: a multicenter pediatric cohort study
Hongbiao Huang et al., BMC Medicine (16 October 2026)
https://doi.org/10.1186/s12916-026-05303-y
- 4.
Restoration of PINK1/Parkin-associated mitophagy via the NAD+/SIRT1 axis attenuates Kawasaki disease vasculitis
Yifei Qin et al., The Journal of Cardiovascular Aging (16 October 2026)
https://doi.org/10.20517/jca.2026.123
- 5.
Kawasaki disease: experience in diagnosis and treatment
M.S. Savvina et al., Yakut Medical Journal (15 October 2026)
https://doi.org/10.25789/ymj.2026.95.35
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Kawasaki Disease
Kawasaki disease is an illness that causes inflammation of blood vessels, mostly in young children. Typical features include prolonged fever, rash, red eyes and lips, swollen hands and feet, and enlarged neck glands. Without prompt treatment it can damage the coronary arteries of the heart. Treatment with intravenous immunoglobulin and aspirin, given early, reduces that risk, and children are followed with heart imaging.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
UNLABELLED: Coronary artery lesions (CAL) are the most common complication of Kawasaki disease (KD). Chinese guidelines recommend aspirin at 30-50 mg/kg/day during the acute phase, yet whether the dose within this range affects coronary outcome remains unclear. We retrospectively analyzed 997 children with complete or incomplete KD who received IVIG plus aspirin at two tertiary hospitals in Sichuan, China, from January 2017 to December 2025. Low-dose aspirin (30 to < 40 mg/kg/day; n = 630) was compared with high-dose (40 to 50 mg/kg/day; n = 367). Confounders were selected by intersecting a directed acyclic graph (Supplementary Fig. S1) with univariate screening at P < 0.10, yielding a final multivariable model of 7 predictors (136 CAL events; events-per-variable ratio of 19.4). Linearity of the continuous covariates and the absence of multicollinearity were verified (Supplementary Tables S1-S2). The dose-response relation was examined with restricted cubic splines, and inverse probability of treatment weighting (IPTW) was added as a sensitivity analysis. CAL at 4 weeks occurred in 13.5% of the low-dose group and 14.7% of the high-dose group (P = 0.658), with an adjusted OR of 0.94 (95% CI 0.64-1.38; P = 0.752). IVIG non-response was similar (4.1% vs 3.8%; P = 0.940), whereas aspirin-related adverse drug reactions were twice as frequent with high-dose aspirin (3.0% vs 6.3%; P = 0.021). The spline showed no significant linear (P = 0.253) or non-linear (P = 0.547) dose-response trend. IPTW yielded an OR of 0.95 (95% CI 0.65-1.38), and the doubly robust estimate was 0.95 (95% CI 0.65-1.40). CONCLUSIONS: Within the guideline-recommended 30-50 mg/kg/day window, no significant differences were detected between low- and high-dose aspirin in coronary or IVIG non-response outcomes, while the lower dose halved adverse drug reactions. Although equivalence cannot be formally demonstrated in an observational study, these data suggest that 30 to < 40 mg/kg/day may be the preferable choice during the acute phase of KD in Chinese children. WHAT IS KNOWN: • Chinese guidelines recommend aspirin at 30-50 mg/kg/day during the acute phase of KD, yet comparative coronary outcome data within this dose range remain limited. WHAT IS NEW: • In a two-center cohort of 997 children, low-dose (30 to < 40 mg/kg/day) and high-dose (40 to 50 mg/kg/day) aspirin produced similar coronary artery lesion rates and IVIG non-response rates, whereas the lower dose halved the rate of adverse drug reactions.
Common Questions
What is Kawasaki Disease?
Kawasaki disease is an illness that causes inflammation of blood vessels, mostly in young children. Typical features include prolonged fever, rash, red eyes and lips, swollen hands and feet, and enlarged neck glands. Without prompt treatment it can damage the coronary arteries of the heart. Treatment with intravenous immunoglobulin and aspirin, given early, reduces that risk, and children are followed with heart imaging.
How many clinical trials are available for Kawasaki Disease?
RareWays currently indexes 38 clinical trials for Kawasaki Disease, of which 6 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Kawasaki Disease come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Kawasaki Disease.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.